Daniel Lawton
Directeur Général chez Promentis Pharmaceuticals, Inc.
Profil
Daniel Lawton is currently the Chief Executive Officer & Director at Promentis Pharmaceuticals, Inc. He previously worked as a Principal at Abbott Laboratories, Vice President & General Counsel at Schwarz Pharma, Inc., and President at Dohmen Co. Mr. Lawton is a graduate of Harvard Law School.
Postes actifs de Daniel Lawton
| Sociétés | Poste | Début |
|---|---|---|
Promentis Pharmaceuticals, Inc.
 Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | Directeur Général | - |
Anciens postes connus de Daniel Lawton
| Sociétés | Poste | Fin |
|---|---|---|
Schwarz Pharma, Inc.
 Schwarz Pharma, Inc. Pharmaceuticals: MajorHealth Technology SCHWARZ PHARMA, Inc. develops and manufactures pharmaceutical products. The company's products include Codimal, Colyte, Edex, Kutrase, Levatol, Robaxin, and Verelan. It was founded in 2003 and is headquartered in Mequon, WI. | Conseiller Juridique Général | - |
| ABBOTT LABORATORIES | Corporate Officer/Principal | - |
Dohmen Co.
 Dohmen Co. Data Processing ServicesTechnology Services Dohmen Co. operates as a retail pharmacy agency that provides outsourced healthcare services. Its services include supply chain, customer and patient support, technology, financial, consulting, and quality and regulatory services. The company was founded by Friedrich W. Dohmen in 1858 and is headquartered in Milwaukee, WI. | President | - |
Formation de Daniel Lawton
| Harvard Law School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| Entreprise privées | 3 |
|---|---|
Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | Health Technology |
Dohmen Co.
Dohmen Co. Data Processing ServicesTechnology Services Dohmen Co. operates as a retail pharmacy agency that provides outsourced healthcare services. Its services include supply chain, customer and patient support, technology, financial, consulting, and quality and regulatory services. The company was founded by Friedrich W. Dohmen in 1858 and is headquartered in Milwaukee, WI. | Technology Services |
Schwarz Pharma, Inc.
Schwarz Pharma, Inc. Pharmaceuticals: MajorHealth Technology SCHWARZ PHARMA, Inc. develops and manufactures pharmaceutical products. The company's products include Codimal, Colyte, Edex, Kutrase, Levatol, Robaxin, and Verelan. It was founded in 2003 and is headquartered in Mequon, WI. | Health Technology |